IMMUNOGLOBINS News & Analysis

Life-changing blood treatments and staggering compound average annual share price growth of 25 per cent since floating on the ASX a quarter-century...

CSL's profit boost and solid outlook have earned it a fair value upgrade, while Pact Group remains undervalued despite a dividend cut and debt woes.